References
- LavanchyDEvolving epidemiology of hepatitis C virusClin Microbiol Infect20111710711521091831
- CornbergMRazaviHAAlbertiAA systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel: systematic review of HCV epidemiology in EuropeLiver Int201131306021651702
- NegroFEpidemiology of hepatitis C in EuropeDig Liver Dis201446S158S16425453870
- BackusLIBelperioPSShahoumianTACheungRMoleLAComparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohortAliment Pharmacol Ther2014399310324206566
- JensenDMO’LearyJPockrosPSafety and efficacy of sofosbuvir-containing regimens for hepatitis C: real-world experience in a diverse, longitudinal observational cohortFifth Annual Meeting of the American Association for the Study of Liver DiseasesNov 7–11, 2014Boston, MA
- HézodeCFontaineHDorivalCTriple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890J Hepatol20135943444123669289
- GutierrezJALawitzEJPoordadFInterferon-free, direct-acting antiviral therapy for chronic hepatitis CJ Viral Hepat20152286187026083155
- MaanRvan TilborgMDeterdingKSafety and effectiveness of direct-acting antiviral agents for treatment of patients with chronic hepatitis C virus infection and cirrhosisClin Gastroenterol Hepatol2016141821.e61830.e627404965
- DieterichDBaconBFlammSEvaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous populationFifth Annual Meeting of the American Association for the Study of Liver DiseasesNov 7–11, 2014Boston, MA
- KwoPGitlinNNahassRSimeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized studyHepatology20166437038026799692
- LawitzEMatusowGDeJesusESimeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2)Hepatology20166436036926704148
- ShiffmanMLJamesAMLongAGAlexanderPCTreatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or ribavirinAm J Gastroenterol20151101179118526215530
- SulkowskiMSGardinerDFRodriguez-TorresMDaclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infectionN Engl J Med201437021122124428467
- ZeuzemSDusheikoGMSalupereRSofosbuvir and ribavirin in HCV genotypes 2 and 3N Engl J Med20143701993200124795201
- Review edition: Highlights in the treatment of hepatitis C virus from the 2014 liver meeting: a review of selected presentations from the 2014 liver meeting November 7–11, 2014Gastroenterol Hepatol201410119
- MehtaRKabrawalaMNandwaniSTekriwalRNandaniaPEarly experience of sofosbuvir based combination therapy in “real-life” cohort with chronic hepatitis-C infectionJ Clin Diagn Res201711OC05OC08
- HlaingNKTMitraniRAAungSTSafety and efficacy of sofosbuvir-based DAA regimens for hepatitis C virus genotypes 1–4 and 6 in Myanmar: real-world experienceJ Viral Hepat2017241192793528475232
- SaxenaVNybergLPaulyMSafety and efficacy of simeprevir/sofosbuvir in hepatitis C-infected patients with compensated and decompensated cirrhosisHepatology20156271572526033798
- NelsonDRCooperJNLalezariJPAll-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III studyHepatology2015611127113525614962
- LawitzEPoordadFBrainardDMSofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosisHepatology20156176977525322962
- MaasoumyBPortKMarkovaAAEligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world settingPLoS One20138e5528523383319
- ThompsonAJMuirAJSulkowskiMSInterleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virusGastroenterology2010139120.e18129.e1820399780
- ReinDBWittenbornJSWeinbaumCMSabinMSmithBDLesesneSBForecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United StatesDig Liver Dis201143667220739252